News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Clinical trials news

Show

From To
Clinical trials
We Love the Jargon, We Hate the Jargon!

This blog post by Angelo Kaggwa-Katumba and Kay Marshall talks about the essential work of connecting journalists and researchers and how advocates are the linchpin.

Published
20 July 2018
From
AVAC
The search for an HIV prevention vaccine
Will an HIV vaccine that protected two-thirds of monkeys do the same for humans?

The Lancet last Friday published the 52-week results of APPROACH, an HIV vaccine whose 28-week results, reported by aidsmap.com last year, were sufficiently impressive for it to

Published
13 July 2018
By
Gus Cairns
Cancer
Superior AIDS-Kaposi’s Sarcoma Treatment Identified

A clinical trial funded by the National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute comparing three chemotherapy regimens in combination with antiretroviral treatment (ART) for treatment of advanced AIDS-Kaposi’s sarcoma patients in Africa and South America has ended early. Interim data showed that participants who were treated with paclitaxel plus ART had better tumor outcomes than participants who received the other treatment regimens.

Published
27 June 2018
From
National Institute of Allergies and Infectious Diseases (NIAID)
PrEP
NHS England considers expanding PrEP trial - NAT comment

Deborah Gold, Chief Executive of NAT (National AIDS Trust) said: “This proposed trial expansion, from 10,000 to 13,000 participants, is essential and we urge NHS England to confirm the decision urgently. This expansion was first proposed by NAT as necessary to estimate accurately the likely long-term needs of a routinely commissioned PrEP programme and it’s great news that this is now on the table.

Published
18 June 2018
From
National AIDS Trust
Clinical trials
My PrEP story: Patrick (part 2)

In his second My PrEP Story blog Dr. Patrick Baxter talks about being on Gilead’s DISCOVER Trial. What’s the trial attempting to do? And why the lack of community consultation? And is he really using PrEP?

Published
10 April 2018
From
Prepster
PrEP
Gay men seeking HIV-preventing PrEP drugs are being ‘turned away’ from sexual health clinics over trial capacity

More than two dozen sexual health clinics in England are now turning away gay men who are seeking to take HIV-preventing drugs, PinkNews has found.

Published
21 March 2018
From
Pink News
New and experimental HIV treatments
Powerful new PrEP and treatment drug should be effective as a small weekly pill

MK-8591 or EFdA is a novel and exceptionally long-lasting and potent HIV drug, being developed by Merck. It is a nucleoside reverse transcriptase translocation inhibitor

Published
12 March 2018
By
Gus Cairns
Microbicides
The vaginal ring: more HOPE to the DREAM? Higher adherence and better effectiveness seen in open-label ring studies

Two open-label, parallel studies of vaginal rings used to prevent HIV in women released interim results at the 25th Conference on Retroviruses and Opportunistic Infections (CROI

Published
08 March 2018
By
Gus Cairns
The biology of HIV transmission
Longstanding Mombasa Cohort helps answer questions about HIV risk and transmission

This month, Fred Hutchinson Cancer Research Center virologist Dr. Julie Overbaugh and her collaborators in Kenya and the U.S. celebrated the 25th anniversary of a unique group of HIV research participants — high-risk women in Mombasa, Kenya — who helped change the landscape of HIV transmission research.

Published
28 February 2018
From
Fred Hutch
Starting treatment
An Exciting Act II for the Study That Proved Treating HIV Early Is Best

With a grant to follow their large study population through 2021, researchers hope to gain vital new insights about HIV infection.

Published
25 February 2018
From
Poz
← Prev1...23456...25Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.